• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体 L858R 和 T790M 突变体不同结构域的相关运动和动力学。

Correlated Motions and Dynamics in Different Domains of Epidermal Growth Factor Receptor With L858R and T790M Mutations.

出版信息

IEEE/ACM Trans Comput Biol Bioinform. 2022 Jan-Feb;19(1):383-394. doi: 10.1109/TCBB.2020.2995569. Epub 2022 Feb 3.

DOI:10.1109/TCBB.2020.2995569
PMID:32750848
Abstract

Non-small cell lung cancer with an activating epidermal growth factor receptor (EGFR) mutation responds well to targeted drugs. In most cases, drug resistance appears after about a year. Several studies have been conducted on the kinase domain of EGFR to understand the drug resistance mechanism. Since EGFR is a multi-domain protein, mutation in the kinase domain may affect the other domains as well. In this study, we examine the complete structure of the multi-domain EGFR protein and its mutants. We performed molecular dynamics simulations for wildtype EGFR, EGFR with L858R mutation, and EGFR with L858R and T790M mutations. We applied normal mode analysis and complex network analysis to extract the correlated motions in the domains of EGFR. The normal modes are used to construct the dynamic cross-correlation map (DCCM). Simulation results show different patterns of correlated motions in each domain of EGFR mutants compared to the wildtype. In Domains 1 and 3 of the extracellular region, a small number of weak positively correlated motions are extracted. Domains 2 and 4 show large numbers of both positive and negative motions. However, the negatively correlated motions are stronger in mutant structures compared to the wildtype. In Domain 7, some residues showed a positive correlation around the main diagonal. We also identified different communities, nodes and crucial residues in the domains of the structures, which can be important for the function of EGFR. Moreover, hydrogen bond analysis is performed for the stability analysis. The mutant structures have fewer hydrogen bonds compared to the wildtype. Overall, these findings are useful for understanding the dynamics and communications in EGFR domains.

摘要

具有激活表皮生长因子受体 (EGFR) 突变的非小细胞肺癌对靶向药物反应良好。在大多数情况下,大约一年后会出现耐药性。已经对 EGFR 的激酶结构域进行了几项研究,以了解耐药机制。由于 EGFR 是一种多结构域蛋白,激酶结构域的突变也可能影响其他结构域。在这项研究中,我们检查了多结构域 EGFR 蛋白及其突变体的完整结构。我们对野生型 EGFR、L858R 突变的 EGFR 和 L858R 和 T790M 突变的 EGFR 进行了分子动力学模拟。我们应用正常模式分析和复杂网络分析来提取 EGFR 结构域中的相关运动。正常模式用于构建动态互相关图 (DCCM)。模拟结果表明,与野生型相比,EGFR 突变体中每个结构域的相关运动模式不同。在细胞外区域的结构域 1 和 3 中,提取了少量弱正相关运动。结构域 2 和 4 显示了大量的正相关和负相关运动。然而,与野生型相比,突变体结构中的负相关运动更强。在结构域 7 中,一些残基在主对角线附近显示出正相关。我们还确定了结构域中不同的社区、节点和关键残基,这对 EGFR 的功能可能很重要。此外,还进行了氢键分析以进行稳定性分析。与野生型相比,突变体结构中的氢键较少。总的来说,这些发现有助于理解 EGFR 结构域中的动力学和通讯。

相似文献

1
Correlated Motions and Dynamics in Different Domains of Epidermal Growth Factor Receptor With L858R and T790M Mutations.表皮生长因子受体 L858R 和 T790M 突变体不同结构域的相关运动和动力学。
IEEE/ACM Trans Comput Biol Bioinform. 2022 Jan-Feb;19(1):383-394. doi: 10.1109/TCBB.2020.2995569. Epub 2022 Feb 3.
2
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.表皮生长因子受体(EGFR)与ErbB-3异源二聚化在非小细胞肺癌治疗中对EGFR突变诱导的吉非替尼和厄洛替尼耐药性的作用
PLoS One. 2015 May 20;10(5):e0128360. doi: 10.1371/journal.pone.0128360. eCollection 2015.
3
Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.表皮生长因子受体(EGFR)突变体的蛋白质稳定性差异决定了对酪氨酸激酶抑制剂的反应性。
Oncotarget. 2016 Oct 18;7(42):68597-68613. doi: 10.18632/oncotarget.11860.
4
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
5
Hydrogen bond analysis of the EGFR-ErbB3 heterodimer related to non-small cell lung cancer and drug resistance.非小细胞肺癌及耐药性相关的 EGFR-ErbB3 异二聚体的氢键分析。
J Theor Biol. 2019 Mar 7;464:63-71. doi: 10.1016/j.jtbi.2018.12.035. Epub 2018 Dec 26.
6
Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry.针对非小细胞肺癌中的 EGFR 和 EGFR 耐药突变:药物化学的最新进展。
Med Res Rev. 2018 Sep;38(5):1550-1581. doi: 10.1002/med.21488. Epub 2018 Jan 26.
7
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.用突变选择性变构抑制剂克服EGFR(T790M)和EGFR(C797S)耐药性。
Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.
8
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.双重 EGFR 突变体含有罕见的 EGFR 突变类型,与常见的激活错义突变相比,体外对吉非替尼的反应降低。
Mol Cancer Ther. 2009 Aug;8(8):2142-51. doi: 10.1158/1535-7163.MCT-08-1219. Epub 2009 Aug 11.
9
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.TAE226,一种双苯胺嘧啶化合物,可抑制包括T790M突变体在内的表皮生长因子受体(EGFR)突变激酶,对EGFR突变的非小细胞肺癌细胞显示出抗肿瘤作用。
PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015.
10
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.表皮生长因子受体(EGFR)中的T790M“守门人”突变介导了对低浓度不可逆EGFR抑制剂的耐药性。
Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

引用本文的文献

1
Molecular Engineering L-Aspartate-Alpha-Decarboxylase to Enhance Catalytic Stability and Performance.通过分子工程改造L-天冬氨酸-α-脱羧酶以增强催化稳定性和性能。
ChemistryOpen. 2025 Feb;14(2):e202400236. doi: 10.1002/open.202400236. Epub 2024 Oct 25.
2
Exploring the Therapeutic Potential of L. Phytochemicals: A Computational Study on Inhibiting SARS-CoV-2's Main Protease (Mpro).探讨 L. 植物化学物质的治疗潜力:抑制 SARS-CoV-2 主要蛋白酶(Mpro)的计算研究。
Molecules. 2024 May 27;29(11):2524. doi: 10.3390/molecules29112524.
3
Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives.
新型计算和药物设计策略,通过芹菜素衍生物抑制人乳头瘤病毒相关宫颈癌和 DNA 聚合酶 θ 受体。
Sci Rep. 2023 Oct 2;13(1):16565. doi: 10.1038/s41598-023-43175-x.
4
AI in drug discovery and its clinical relevance.人工智能在药物研发中的应用及其临床意义。
Heliyon. 2023 Jul;9(7):e17575. doi: 10.1016/j.heliyon.2023.e17575. Epub 2023 Jun 26.
5
Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and study.噻唑并-[2,3-b]喹唑啉酮衍生物与表皮生长因子受体酪氨酸激酶结构域(EGFR-TKD)的构象稳定性和结合的结构见解及研究
Saudi J Biol Sci. 2022 Dec;29(12):103478. doi: 10.1016/j.sjbs.2022.103478. Epub 2022 Oct 27.
6
Machine learning based personalized drug response prediction for lung cancer patients.基于机器学习的肺癌患者个体化药物反应预测。
Sci Rep. 2022 Nov 7;12(1):18935. doi: 10.1038/s41598-022-23649-0.
7
In Silico Drug Repurposing Approach: Investigation of FadD32 Targeted by FDA-Approved Drugs.计算机药物再利用方法:对 FDA 批准药物靶向的 FadD32 的研究。
Molecules. 2022 Jan 20;27(3):668. doi: 10.3390/molecules27030668.